Investigational drug · Phase 3
PJ009
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Short Bowel Syndrome.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "PJ009"
First trial start
2024
Sep 3, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PJ009", any sponsor or status.
Conditions studied
As listed on its trial records.
- Short Bowel Syndrome
Approved drugs for the same conditions: Rare and genetic disease · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "PJ009" as an intervention, largest first.
- Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral NutritionPivotal-lookingActive, not recruiting
Chongqing Peg-Bio Biopharm Co., Ltd.Industry
NCT06512584 · 72 participants (planned) · Start Sep 3, 2024 · Primary completion Sep 28, 2026
Drug: PJ009; PJ009 Placebo · For: Short Bowel Syndrome
Sites: Beijing, China; Chongqing, China; Guangzhou, China · 8 sites in all
Chongqing Peg-Bio Biopharm Co., Ltd.Industry
NCT06523101 · 24 participants · Start Feb 28, 2023 · Primary completion May 15, 2023
Drug: PJ009; Placebo · For: Short Bowel Syndrome
Sites: Taiyuan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Short Bowel Syndrome
- GlepaglutideZP1848Phase 34 trials
Zealand Pharma · Short Bowel Syndrome, Short Bowel Syndrome (SBS)
- ApraglutidePhase 32 trials
VectivBio AG · Short Bowel Syndrome (SBS), SBS Associated With Intestinal Failure (SBS-IF), Short Bowel Syndrome
- Crofelemer forPhase 32 trials
Napo Pharmaceuticals, Inc. · Microvillus Inclusion Disease, Congenital Disorders, Rare Diseases
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.